MicroRNAs from peripheral blood mononuclear cells as biomarkers for detection of preclinical fibrosarcoma 
Materials and methods
We used a model system in which groups of immunocompetent BALB-c mice were subcutaneously injected with different numbers of tumorigenic B61 fibrosarcoma cells. The groups of study were: (i) tumoral group with serial injections of 10 2 to 10 6 cells; (ii) negative control group represented by sterile nonpyrogenic saline, (iii) inflammation group by Zymozan (Sigma) and (iv) bacterial infection group by injection of 10 7 colony forming units [cfu] pool from mice feces. Mouse peripheral blood was collected three days after injection; blood samples (N=10) were pooled according to experimental conditions. Mononuclear cells were separated by centrifugation on a FicollHypaque cushion (GE Healthcare) and RNA was extracted using Trizol Reagent (Invitrogen). Samples were hybridizated on miRNA microarrays (Agilent).
Results
We identified four microRNAs, miR-451, miR-144, miR-486 and miR-494, which were differentially expressed when compared to control groups, including inflammation and bacterial infection.
Conclusions
Our results showed that PBMC microRNA expression profiling can serve as a sensitive method for detection of preclinical cancer.
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